Rural Georgians may find it difficult to access medication that could slow the progression of Alzheimer's disease, according ...

Significant adverse events — such as ARIA — with lecanemab, the drug that slows Alzheimer's, is rare and manageable, ...

Treating early Alzheimer's disease patients with lecanemab (Leqembi) was feasible and most patients tolerated the drug well, a retrospective study at one specialty memory clinic showed.

New data show that lecanemab is well tolerated outside of clinical trial setting, with expected and manageable side effects.

In 2023, the Food and Drug Administration (FDA) approved lecanemab, a new therapy for Alzheimer’s disease. This approval ...

Adoption of lecanemab, a novel infusion treatment for Alzheimer’s disease (AD), has been disproportionately higher among ...

Access to a new Alzheimer’s treatment, lecanemab, shows major disparities tied to race, gender, and income. Disparities in ...

Treatment of Alzheimer disease with lecanemab is feasible in a specialty memory clinic, and the frequency of significant ...

The Food and Drug Administration's approval in 2023 of lecanemab—a novel Alzheimer's therapy shown in clinical trials to modestly slow disease progression—was met with enthusiasm by many in the field ...

A world-first brain scanning technique could identify signs of Alzheimer’s disease long before symptoms appear. The method, ...

Treatment with lecanemab infusion was safe and generally well-tolerated within an outpatient memory clinic setting, with few infusion-related reactions and a low number of withdrawals due to adverse ...

The analysis included 234 patients with early symptomatic Alzheimer disease initiating lecanemab. HealthDay News — Treatment of Alzheimer disease with lecanemab is feasible in a specialty memory ...